Proton-Pump Inhibitors in Patients Requiring Antiplatelet Therapy: New FDA Labeling

References

• . Jneid H, Anderson JL, Wright RS, . 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60(7):645–681
   PubMed Web of Science ®Google Scholar
• . O'Gara PT, Kushner FG, Ascheim DD, . 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362–e425
   PubMed Web of Science ®Google Scholar
• . Yusuf S, Zhao F, Mehta SR, . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502
   PubMed Web of Science ®Google Scholar
• . Abraham NS, Hlatky MA, Antman EM, . ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol. 2010;105(12):2533–2549
   PubMed Web of Science ®Google Scholar
• . , ACTIVE InvestigatorsConnolly SJ, Pogue J, Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066–2078
   PubMed Web of Science ®Google Scholar
• . Ray WA, Murray KT, Griffin MR, . Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: A cohort study. Ann Intern Med. 2010;152(6):337–345
   PubMed Web of Science ®Google Scholar
• . Lanas A, Garcia-Rodriguez LA, Arroyo MT, . Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007;102(3):507–515
   PubMed Web of Science ®Google Scholar
• . Bhatt DL, Cryer BL, Contant CF, . Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–1917
   PubMed Web of Science ®Google Scholar
• . Grines CL, Bonow RO, Casey DE Jr, . Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;115(6):813–818
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. FDA Announces New Warning on Plavix: Avoid Use with Prilosec/Prilosec OTC. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm191169.htm. Accessed November 22, 2013
   Google Scholar
• . Plavix (clopidogrel bisulfate). Full prescribing information. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; 2011
   Google Scholar
• . Chan FK, Ching JY, Hung LC, . Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005;352(3):238–244
   PubMed Web of Science ®Google Scholar
• . Lai KC, Chu KM, Hui WM, . Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol. 2006;4(7):860–865
   PubMed Web of Science ®Google Scholar
• . Maloney JP, Silliman CC, Ambruso DR, Wang J, Tuder RM, Voelkel NF. In vitro release of vascular endothelial growth factor during platelet aggregation. Am J Physiol. 1998;275(3 pt 2):H1054–H1061
   Google Scholar
• . Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA. 2001;98(11):6470–6475
   PubMed Web of Science ®Google Scholar
• . van Hecken A, Depre M, Wynants K, . Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. Drug Metabol Drug Interact. 1998;14(3):193–205
   PubMedGoogle Scholar
• . Catalina Health. Catalina Health Rx Patient Panel. January 1–March 31, 2012
   Google Scholar
• . Dexilant (dexlansoprazole). Full prescribing information. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2012
   Google Scholar
• . Nexium (esomeprazole magnesium). Full prescribing information. Wilmington, DE: AstraZeneca LP; 2012
   Google Scholar
• . Prevacid (lansoprazole). Full prescribing information. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2012
   Google Scholar
• . Prilosec (omeprazole). Full prescribing information. Wilmington, DE: AstraZeneca LP; 2012
   Google Scholar
• . Protonix (pantoprazole sodium). Full prescribing information. Konstanz, Germany: Nycomed GmbH; 2012
   Google Scholar
• . Aciphex (rabeprazole sodium). Full prescribing information. Woodcliff Lake, NJ: Eisai Inc.; 2013
   Google Scholar
• . Mega JL, Close SL, Wiviott SD, . Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119(19):2553–2560
   PubMed Web of Science ®Google Scholar
• . Simon T, Verstuyft C, Mary-Krause M, . Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–375
   PubMed Web of Science ®Google Scholar
• . Shuldiner AR, O'Connell JR, Bliden KP, . Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–857
   PubMed Web of Science ®Google Scholar
• . O'Donoghue ML, Braunwald E, Antman EM, . Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989–997
   PubMed Web of Science ®Google Scholar
• . Frelinger AL 3rd, Lee RD, Mulford DJ, . A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304–1311
   PubMed Web of Science ®Google Scholar
• . Déry JP. SPICE: a prospective, randomized trial of four antacid strategies in patients receiving clopidogrel. Presented at the Transcatheter Cardiovascular Therapeutics conference; November 9, 2011; San Francisco, CA
   Google Scholar
• . Moukarbel GV, Bhatt DL. Antiplatelet therapy and proton pump inhibition: Clinician update. Circulation. 2012;125(2):375–380
   PubMed Web of Science ®Google Scholar
• . Depta JP, Bhatt DL. Antiplatelet therapy and proton pump inhibition: Cause for concern? Curr Opin Cardiol. 2012;27(6):642–650
   PubMed Web of Science ®Google Scholar
• . Kwok CS, Loke YK. Meta-analysis: The effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther. 2010;31(8):810–823
   PubMed Web of Science ®Google Scholar
• . Siller-Matula JM, Jilma B, Schror K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: A systematic review and meta-analysis. J Thromb Haemost. 2010;8(12):2624–2641
   PubMed Web of Science ®Google Scholar
• . Andersson T, Nagy P, Niazi M, Nylander S, Wallentin L. Impact of omeprazole (OME), esomeprazole (ESO) +/- acetylsalicylic acid (ASA) and lansoprazole (LAN) on the pharmacodynamics (PD) and pharmacokinetics (PK) of clopidogrel in healthy volunteers. Eur Heart J. 2012;33(abstr suppl):343
   Web of Science ®Google Scholar
• . Parri MS, Gianetti J, Dushpanova A, . Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: Results of a pilot randomized trial. Int J Cardiol. 2013;167(5):2177–2181
   PubMed Web of Science ®Google Scholar
• . Ng FH, Wong SY, Lam KF, . Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology. 2010;138(1):82–88
   PubMed Web of Science ®Google Scholar
• . Effient (prasugrel). Full prescribing information. Indianapolis, IN: Eli Lilly and Company; 2012
   Google Scholar
• . Brilinta (ticagrelor). Full prescribing information. Wilmington, DE: AstraZeneca LP; 2011
   Google Scholar
• . Antman EM, Wiviott SD, Murphy SA, . Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: A TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction) analysis. J Am Coll Cardiol. 2008;51(21):2028–2033
   PubMed Web of Science ®Google Scholar
• . Cannon CP, Harrington RA, James S, . Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): A randomised double-blind study. Lancet. 2010;375(9711):283–293
   PubMed Web of Science ®Google Scholar
• . Angiolillo DJ, Gibson CM, Cheng S, . Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: Randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65–74
   PubMed Web of Science ®Google Scholar
• . Paris B, Yerino P, Ogilvie B, Parkinson A. The proton pump inhibitors (PPIs) omeprazole and rabeprazole but not lansoprazole and pantoprazole are in vitro time-dependent inhibitors of CYP2C19. Drug Metab Rev. 2008;40:89–90
   Web of Science ®Google Scholar